CSL Limited (ASX: CSL) - Share Price
Current share price for CSL : $127.930 0.14 (0.11%)+
CSL (CSL Limited), an ASX-listed company, is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology.
CSL General Information +
| ASX Code | CSL |
| Website | N/A |
| Industry/Sector | Biotechnology |
| Market Cap ($M) | 61,267 |
| CSL Share Price | $127.930 |
| Day High | $128.990 |
| Day Low | $125.710 |
| Last Close | $128.070 |
| CSL Share Price Movement | $0.14 ( 0.11% ) |
Prices as at 16:40, 30 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
CSL Limited (CSL) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Result | $1.81 | 0% | 10 Mar 2026 | 9 Apr 2026 | - | - | - |
| HFResult | $2.45 | 0% | 9 Sep 2025 | 3 Oct 2025 | - | - | - |
| Result | $2.07 | 0% | 10 Mar 2025 | 9 Apr 2025 | - | - | - |
See all dividends from CSL Limited (CSL) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
CSL Limited (CSL) price-sensitive announcements
CSL - CSL Update on Enhanced Plasma Manufacturing
CSL Limited announced plans to commence clinical trials for its Horizon 2 plasma manufactu
CSL Limited (CSL)
29 Jul 2026 | 9:21 AM
29 Jul 2026 | 9:21 AM
CSL - Interim CEO 90 Day Review and Financial Update
CSL Limited's Interim CEO, Gordon Naylor, provided a comprehensive 90-day review of the co
CSL Limited (CSL)
11 May 2026 | 8:15 AM
11 May 2026 | 8:15 AM
CSL - CSL Half Year Results Investor Presentation
CSL Limited's Half Year Results Investor Presentation for the financial year 1H26 highligh
CSL Limited (CSL)
11 Feb 2026 | 7:46 AM
11 Feb 2026 | 7:46 AM
CSL - CSL Half Year Results Announcement
CSL Limited announced its half-year financial results for the period ending December 2025,
CSL Limited (CSL)
11 Feb 2026 | 7:41 AM
11 Feb 2026 | 7:41 AM
CSL Limited (CSL) Recent ASX Announcements
CSL Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026F | $5,692.27 | $1,172.70 | 14.40% | 23.05 | 516.08 | 1.91% | 0.0% |
| 2025F | $4,974.44 | $1,024.81 | 15.10% | 26.38 | 451.14 | 1.67% | 0.0% |
| 2024A | $4,318.18 | $889.99 | 11.10% | 30.63 | 392.16 | 1.44% | 0.0% |
CSL Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 F | 2026 F | 2024 A | 2025 F | 2026 F | 2024 A | 2025 F | 2026 F | ||
| CSL Limited (CSL) | $57,240M | 0.1108 | -0.1194 | 0.0168 | 12.8162 | 14.5536 | 14.3138 | 3.73% | 3.05% | 3.17% |
| Clinuvel Pharmaceuticals Limited (CUV) | $495M | 0.0287 | 0.0000 | 0.0000 | 13.6630 | 0.0000 | 0.0000 | 0.51% | 0.00% | 0.00% |
| Immutep Limited (IMM) | $69M | 0.1854 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Mesoblast Limited (MSB) | $2,675M | 0.0301 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Telix Pharmaceuticals Limited (TLX) | $4,917M | -1.3893 | 0.0000 | -0.4221 | 0.0000 | 159.8895 | 276.6730 | 0.00% | 0.00% | 0.00% |
CSL Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Gordon Naylor | Chief Executive Officer, Managing Director | 1 Dec 2025 |
| Ms Carolyn Judith Hewson | Non-Executive Director | 9 Dec 2019 |
| Ms Alison Mary Watkins | Non-Executive Director | 18 Aug 2021 |
| Dr Robert Andrew Cuthbertson | Non-Executive Director | 17 Oct 2018 |
| Ms Samantha (Sam) Louise Lewis | Non-Executive Director | 1 Jan 2024 |
| Ms Elaine Sorg | Non-Executive Director | 1 Sep 2024 |
| Dr Brian Daniels | Non-Executive Director | 1 Dec 2024 |
| Mr Cameron Bruce Price | Non-Executive Director | 1 Oct 2025 |
| Mr Constantine Saroukos | Non-Executive Director | 1 Dec 2025 |
| Dr Brian Anthony McNamee | Non-Executive Director, Non-Executive Chairman | 13 Feb 2018 |
CSL Limited (CSL) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 1 Jun 2026 | HEWSON, Carolyn | Buy | Indirect Shares | 1,036 | $95.890 | $99,342.040 |
| 26 May 2026 | NAYLOR, Gordon | Buy | Indirect Shares | 1,100 | $98.000 | $107,800.000 |
| 15 May 2026 | WATKINS, Alison | Buy | Indirect Shares | 2,540 | $98.660 | $250,595.380 |
See all changes in directors' interest & trades for CSL Limited (CSL) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
CSL Management
| Name | Position |
|---|---|
| Kate Priestman | Chief Corporate & External Affairs Officer |
| Joy Linton | Chief Financial Officer |
| Roanne Parry | Chief Human Resources Officer |
| Mary Oates | Chief Operating Officer |
| Fiona Mead | Company Secretary,Head of Group Governance |
| Ken Lim | Executive Vice President and Chief Strategy Officer |
| Andy Schmeltz | Executive Vice President, CSL Behring |
| Mark Hill | Executive Vice President, Chief Digital Information Officer |
| Bill Mezzanotte | Executive Vice President, Head of Research & Development and Chief Medical Officer |
| Greg Boss | Executive Vice President, Legal and CSL Group General Counsel |
| Herve Gisserot | Senior Vice President and General Manager CSL Vifor |
| Dave Ross | Senior Vice President and General Manager CSL Seqirus |
| John Levy | Senior Vice President Enterprise Accelerator |
CSL Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in CSL Limited (CSL). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 34,450,667 (7.11%) | State Street Corporation and subsidiaries |
| 27,353,205 (5.65%) | BlackRock Group |
| 24,112,875 (4.98%) | The Vanguard Group,Inc |
CSL Calendar of Events
| Date | Event |
|---|---|
| 10 February 2027 | Report (Interim) |
| 18 August 2026 | Report (Annual) |
| 18 August 2026 | Report (Prelim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
